Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained ...

Denali Therapeutics Inc. (NASDAQ:DNLI) recently reported results from its phase 2/3 HEALEY ALS Platform Trial using DNL343 for the treatment of patients with Amyotrophic Lateral Sclerosis [ALS].

Denali Therapeutics Inc. DNLI announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, tividenofusp alfa (DNL310), for the treatment of individuals with ...

DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the HEALEY trial.

For the primary analysis, a total of 186 participants who received DNL343 treatment were compared to 139 participants who ...

In studies by Massachusetts General Hospital, the AbbVie-Calico collaborative drug and Denali Therapeutics' own drug failed to meet endpoints for treating amyotrophic lateral sclerosis, more widely ...

Overall, according to the release, DNL343 was “safe and well tolerated.” DNL343 was developed to target eIF2B, a central regulator of the integrated stress response (ISR), which is overactive ...

Denali Therapeutics recently disclosed the outcomes of its HEALEY trial, which evaluated DNL343, an agonist of eIF2B intended for the treatment of amyotrophic lateral sclerosis (ALS). The trial failed ...

A study of human brain organoids suggested a complex relationship between herpes simplex virus 1 infection and tau, suggesting that tau phosphorylation may act as an innate immune response in ...

The revision followed the announcement that Denali's DNL343, an eIF2B inhibitor, did not achieve the primary or key secondary endpoints in the phase 2/3 HEALEY trial for amyotrophic lateral sclerosis ...